A newly identified disease called Plasticosis is scarring the tissue of seabirds, and probably us as well. Its cause: microplastic pollution.
Plasticosis or Plastic-Induced Fibrotic Disease has been discovered in seabirds caused by ingesting microplastic pollution.
NPL, in collaboration with London Biofoundry and BiologIC Technologies Ltd, have released an analysis on existing and emerging DNA Synthesis technologies in Nature Reviews Chemistry, featuring the work on the front cover.
The study, which was initiated by DSTL, set out to understand the development trajectory of DNA Synthesis as a major industry drive for the UK economy over the next 10 years. The demand for synthetic DNA is growing exponentially. However, our ability to make, or write, DNA lags behind our ability to sequence, or read, it. The study reviewed existing and emerging DNA synthesis technologies developed to close this gene writing gap.
DNA or genes provide a universal tool to engineer and manipulate living systems. Recent progress in DNA synthesis has brought up limitless possibilities in a variety of industry sectors. Engineering biology, therapy and diagnostics, data storage, defense and nanotechnology are all set for unprecedented breakthroughs if DNA can be provided at scale and low cost.
“That’s got molecules in it that will prevent cancer, among other things” like anti-inflammatory properties, he said. Some older research has shown, for example, that green tea consumption might be linked to a lower risk of stomach cancer.
Sinclair also said he takes supplements (like those sold on the Tally Health website) that contain resveratrol, which his team’s research has shown can extend the lifespan of organisms like yeast and worms.
While the compound, famously found in red wine, is known to have anti-inflammatory, anti-cancer, heart health, and brain health benefits, the research is mixed on if or how well such benefits can be achieved in humans through a pill.
Artificial intelligence is no longer a futuristic idea. It’s already here, and it has turned out to be a powerful, disruptive force in healthcare fueling some of the most innovative diagnostic tools of today.
Let’s take a look at 7 examples where AI has started to transform healthcare!
FallenKingdomReads’ list of The Top 5 Science Fiction Books That Explore the Ethics of Cloning.
Cloning is a topic that has been explored in science fiction for many years, often raising questions about the ethics of creating new life forms. While the idea of cloning has been discussed in various forms of media, such as movies and TV shows, some of the most interesting and thought-provoking discussions on the topic can be found in books. Here are the top 5 science fiction books that explore the ethics of cloning.
Alastair Reynolds’ House of Suns is a space opera that explores the ethics of cloning on a grand scale. The book follows the journey of a group of cloned human beings known as “shatterlings” who travel the galaxy and interact with various other sentient beings. The book raises questions about the nature of identity and the value of individuality, as the shatterlings face challenges that force them to confront their own existence and the choices they have made.
One Health Approaches To Prevent Zoonoses & Antimicrobial Resistance — Dr. Keith Sumption, Ph.D. — Chief Veterinary Officer and Leader of the Animal Health Program; Director, Joint Centre for Zoonoses and Anti-Microbial Resistance (CJWZ), Food and Agriculture Organization of the United Nations (FAO)
Dr. Keith Sumption, Ph.D. is Chief Veterinary Officer and Leader of the Animal Health Program at the Food and Agriculture Organization of the United Nations (FAO — https://www.fao.org/home/en) as well as their Director of the Joint Centre for Zoonoses and Anti-Microbial Resistance (CJWZ).
A new concept called organoid intelligence, with the aim of developing a new generation of biocomputers, has recently been detailed by a group of researchers. They want to harness advances in the reproduction of human brain cells in vitro to offer superior intelligence to the computers and smart devices of the future. This technology promises to be much more powerful and efficient than any form of artificial intelligence as we know it.
This notion of organoid intelligence is described in a paper outlining a roadmap to developing this technology published in the journal Frontiers of Science, by numerous scientists, mainly from Johns Hopkins University in Baltimore. According to them, work on cerebral organoids, derived from human stem cells, should make it possible in the relatively near future to reproduce entities endowed with memory and a genuine capacity for learning. Organoids are miniature organs grown in vitro. The term organoid intelligence (OI) encompasses all these developments, leading to a form of biological computing — or biocomputing — that leverages neurons bred in a lab. All of which is enough to make the likes of ChatGPT seem outdated already.
Complex interfaces could eventually be networked, with brain organoids connected to sensory organoids such as retinal organoids. This could, for example, lead to new therapeutic applications.
Driving Toward the Elimination of Cancer — Joel Greshock — VP, Oncology, Data Science & Digital Health, Janssen Pharmaceutical Companies of Johnson & Johnson.
Joel Greshock is VP, Oncology, Data Science & Digital Health, Janssen Research & Development (https://www.janssen.com/oncology/leadership-team). In this position, he is responsible for creating unique and actionable medical insights using large and increasingly available datasets. The focus of this research includes discovering novel therapeutic targets, identifying areas of unmet medical need, and enhancing clinical trial recruitment and execution.
https://youtube.com/watch?v=uYjjRAcI7x4
For copyright contact: stienlemane2379(at)gmail.com.
Welcome to Futureunity, where we explore the fascinating world of science, technology, and the universe! From the inner workings of the human body to the outer reaches of space, we delve into the latest and most interesting discoveries that are shaping our world. Whether you’re a science buff or just looking for some mind-blowing facts, we’ve got you covered. Join us as we uncover the mysteries of the world around us and discover new frontiers in the fields of science and technology. Get ready for a journey that’s both educational and entertaining!
Continue reading “6 Theories About What Lies Outside The Observable Universe!” »
In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents in all diseased arteries was found to be as safe and effective at one year of follow-up as staged treatment, according to findings from the first large, randomized trial to address this question that is being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. In staged treatment, the blocked artery that caused the heart attack is treated with a stent immediately and other partially blocked arteries are treated in a second procedure up to six weeks later. This study was simultaneously published online in The Lancet at the time of presentation.
About half of patients who have a heart attack have multi-vessel heart disease—this means that in addition to having one completely blocked coronary artery that caused their heart attack, they have additional narrowed coronary arteries that are at risk of becoming blocked or unstable, leading to another heart attack. Clinicians refer to the blocked artery that causes a heart attack as the “culprit lesion” and to the other at-risk arteries as “non-culprit lesions.”
“The purpose of the international, randomized BIOVASC trial was to compare outcomes for immediate and staged complete revascularization for patients with multi-vessel heart disease who have suffered a heart attack. The goal was not to determine which approach was superior but rather to establish whether immediate complete vascularization was ‘not inferior’ to the staged approach, which needed to be answered first,” said Roberto Diletti, MD, Ph.D., an interventional cardiologist at Erasmus Medical Center in Rotterdam, Netherlands, and lead author of the study.
